Skip to content

Adherence and Intensification of Medications (AIM) Implementation Study

Adherence and Intensification of Medications: A Population-Based Clinical Pharmacists Implementation Study Among Hypertensive Diabetes Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00495794
Enrollment
4622
Registered
2007-07-03
Start date
2008-08-31
Completion date
2012-07-31
Last updated
2015-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Hypertension

Keywords

diabetes, hypertension, adherence, implementation, medications, organization of care

Brief summary

Background: Good blood pressure (BP) control among patients with diabetes is essential in preventing diabetes complications and has been found to be not only cost-effective but cost-saving. Nonetheless, over 25% of VA patients with diabetes do not have adequate BP control. Among these poorly controlled patients, over 65% have problems with medication adherence or inadequate intensification of medications. We therefore propose a partnership with the VA Pharmacy Benefits Management (PBM) Office and VISN 11 to evaluate a tailored clinical pharmacist-based intervention to improve medication management, adherence and BP control. Objectives: The specific objectives of this implementation study are: 1) To evaluate the effects of the intervention on blood pressure (primary outcome) and glycemic and lipid control (secondary outcomes); 2) To assess the impact of the intervention on patients' adherence to blood pressure, anti-hyperglycemic, and lipid-lowering regimens, and intensity of these regimens; 3) To evaluate the cost-effectiveness of the intervention compared to usual care; 4) To evaluate the level of attainment of intervention implementation, examine the process of intervention implementation, and determine the potential for sustainability.

Detailed description

Background: Good blood pressure (BP) control among patients with diabetes is essential in preventing diabetes complications and has been found to be not only cost-effective but cost-saving. Nonetheless, over 25% of VA patients with diabetes do not have adequate BP control. Among these poorly controlled patients, over 65% have problems with medication adherence or inadequate intensification of medications. We therefore propose a partnership with the VA Pharmacy Benefits Management (PBM) Office and VISN 11 to evaluate a tailored clinical pharmacist-based intervention to improve medication management, adherence and BP control. Objectives: The specific objectives of this implementation study are: 1) To evaluate the effects of the intervention on blood pressure (primary outcome) and glycemic and lipid control (secondary outcomes); 2) To assess the impact of the intervention on patients' adherence to blood pressure, anti-hyperglycemic, and lipid-lowering regimens, and intensity of these regimens; 3) To evaluate the cost-effectiveness of the intervention compared to usual care; 4) To evaluate the level of attainment of intervention implementation, examine the process of intervention implementation, and determine the potential for sustainability. Methods: In this cluster randomized implementation trial, we will proactively identify, using clinical automated data, all diabetes patients within 3 VA sites who have poor blood pressure control and either poor refill adherence or insufficient medication intensification. (NIDDK R18 funds 2 non-VA sites.) Adherence and treatment intensification patterns will also be evaluated for glycemia and lipids if either of these risk factors is poorly controlled. Clinical pharmacists, trained in motivational interviewing techniques and guided by computerized adherence modules, will identify barriers to medication adherence and provide adherence counseling. They will also be authorized to change and titrate medications following site-specific algorithms. Patients in the non-intervention (control) teams will receive usual care. Blood pressure control and refill adherence will be assessed 6-months after the end of the intervention period. We will also conduct a formative evaluation during the course of the study and assess implementation attainment and potential for dissemination. Status: Data analysis complete. (Enrollment numbers are for VA and non-VA sites \[control and intervention\].)

Interventions

BEHAVIORALClinical pharmacist-based intervention

Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
Kaiser Permanente
CollaboratorOTHER
US Department of Veterans Affairs
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

VA inclusion criteria 1. Must be a veteran at a study site; 2. Have a diagnosis of diabetes; 3. Meet blood pressure, medication adherence and intensification requirements (as determined by the study team)

Exclusion criteria

VA Exclusion 1. Dementia 2. Traumatic brain injury 3. Pregnancy 4. Age \<18 or \>100

Design outcomes

Primary

MeasureTime frame
Change in Systolic Blood Pressure6 months prior to 6 months after the intervention period

Secondary

MeasureTime frame
A1c Control12 months after intervention period
LDL Control12 months after invention period

Countries

United States

Participant flow

Participants by arm

ArmCount
Pharmacist Management
Eligible patients assigned to - adherence counseling and medication management delivered by a clinical pharmacist trained in behavioral counseling approaches (motivational interviewing) Clinical pharmacist-based intervention: Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms
1,797
Usual Care
Eligible patients receive usual care
2,303
Total4,100

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyPharmacist did not activate patient5220

Baseline characteristics

CharacteristicPharmacist ManagementUsual CareTotal
Age, Continuous65.3 years
STANDARD_DEVIATION 11.7
65.3 years
STANDARD_DEVIATION 12.1
65.3 years
STANDARD_DEVIATION 11.9
Region of Enrollment
United States
1797 participants2303 participants4100 participants
Sex: Female, Male
Female
547 Participants721 Participants1268 Participants
Sex: Female, Male
Male
1250 Participants1582 Participants2832 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 2,3190 / 2,303
serious
Total, serious adverse events
0 / 2,3190 / 2,303

Outcome results

Primary

Change in Systolic Blood Pressure

Time frame: 6 months prior to 6 months after the intervention period

Population: intention to treat analysis

ArmMeasureValue (MEAN)
Pharmacist ManagementChange in Systolic Blood Pressure-8.9 mmHg
Usual CareChange in Systolic Blood Pressure-9.0 mmHg
Secondary

A1c Control

Time frame: 12 months after intervention period

Population: Includes only participants with an A1c in the 12 months after the intervention period.

ArmMeasureValue (MEAN)Dispersion
Pharmacist ManagementA1c Control7.4 percentage of total hemoglobinStandard Deviation 1.4
Usual CareA1c Control7.6 percentage of total hemoglobinStandard Deviation 1.6
Secondary

LDL Control

Time frame: 12 months after invention period

Population: Includes only participants with a LDL in the 12 months after the intervention period.

ArmMeasureValue (MEAN)Dispersion
Pharmacist ManagementLDL Control89.1 mg/dlStandard Deviation 31.1
Usual CareLDL Control87.8 mg/dlStandard Deviation 32.9

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026